Reply

Freekje van Asten¹, Chi-Yang Chiu², Elvira Agrón³, Traci E Clemons⁴, Rinki Ratnapriya¹, Anand Swaroop¹, Michael L Klein⁵, Ruzong Fan⁶, Emily Y Chew⁷

Affiliations

¹ Neurobiology-Neurodegeneration & Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
² Department of Preventive Medicine, University of Tennessee, Knoxville, Tennessee.
³ Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
⁴ The EMMES Corporation, Rockville, Maryland.
⁵ Casey Eye Institute, Oregon Health & Science University, Portland, Oregon.
⁶ Department of Biostatistics, Bioinformatics & Biomathematics, Georgetown University Medical Center, Washington, DC.
⁷ Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: echew@nei.nih.gov.

PMID: 32087877
PMCID: PMC8336683
DOI: 10.1016/j.ophtha.2019.10.033

Comment

Reply

Freekje van Asten et al. Ophthalmology. 2020 Mar.

. 2020 Mar;127(3):e19-e20.

doi: 10.1016/j.ophtha.2019.10.033.

Authors

Freekje van Asten¹, Chi-Yang Chiu², Elvira Agrón³, Traci E Clemons⁴, Rinki Ratnapriya¹, Anand Swaroop¹, Michael L Klein⁵, Ruzong Fan⁶, Emily Y Chew⁷

Affiliations

¹ Neurobiology-Neurodegeneration & Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
² Department of Preventive Medicine, University of Tennessee, Knoxville, Tennessee.
³ Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
⁴ The EMMES Corporation, Rockville, Maryland.
⁵ Casey Eye Institute, Oregon Health & Science University, Portland, Oregon.
⁶ Department of Biostatistics, Bioinformatics & Biomathematics, Georgetown University Medical Center, Washington, DC.
⁷ Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: echew@nei.nih.gov.

PMID: 32087877
PMCID: PMC8336683
DOI: 10.1016/j.ophtha.2019.10.033

No abstract available

PubMed Disclaimer

Conflict of interest statement

Financial Disclosures: The authors have no proprietary or commercial interest in any materials discussed in this article.

Comment on

No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18.
van Asten F, Chiu CY, Agrón E, Clemons TE, Ratnapriya R, Swaroop A, Klein ML, Fan R, Chew EY; Age-Related Eye Disease Study 2 Research Group. van Asten F, et al. Ophthalmology. 2019 Nov;126(11):1541-1548. doi: 10.1016/j.ophtha.2019.06.004. Epub 2019 Jun 12. Ophthalmology. 2019. PMID: 31358387 Free PMC article. Clinical Trial.
Re: Van Asten et al.: No CFH/ARMS2 interaction with omega-3 fatty acids, low vs high zinc, or β-carotene versus Lutein and Zeaxanthin on progression of age-related macular degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18 (Ophthalmology. 2019;126:1541-1548).
Zanke B, Kustra R. Zanke B, et al. Ophthalmology. 2020 Mar;127(3):e19. doi: 10.1016/j.ophtha.2019.10.032. Ophthalmology. 2020. PMID: 32087876 No abstract available.

References

1. Chew EY, Klein ML, Clemons TE, et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology. 2014; 121:2173–2180. - PMC - PubMed
1. Chew EY, Klein ML, Clemons TE, et al. Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test? Ophthalmology. 2015;122:212–215. - PMC - PubMed
1. Assel MJ, Li F, Wang Y, et al. Genetic polymorphisms of CFH and ARMS2 do not predict response to antioxidants and zinc in patients with age-related macular degeneration: independent statistical evaluations of data from the Age-Related Eye Disease Study. Ophthalmology. 2018;125: 391–397. - PMC - PubMed
1. Awh CC, Lane AM, Hawken S, et al. CFH and ARMS 2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology. 2013;120:2317–2323. - PubMed
1. Awh CC, Hawken S, Zanke BW. Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease Study. Ophthalmology. 2015;122:162–169. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Grants and funding

ZIA EY000485/ImNIH/Intramural NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply

Affiliations

Reply

Authors

Affiliations

Conflict of interest statement

Comment on

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical